Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in noninhibitor patients) and bypass agents (in inhibitor patients). The main goal of factor IX prophylaxis and bypass agent treatment is to improve the quality of life of patients by reducing the frequency and severity of bleeding episodes. The hemophilia B therapy market will be transformed over the next 10 years owing to the entry of gene therapies and nonfactor therapies. In November 2022, the FDA approved Hemgenix (CSL Behring), the first gene therapy for hemophilia B. Fidanacogene elaparvovec (Pfizer) is the other key gene therapy in development. Upcoming novel subcutaneous nonfactor therapies will offer effective alternatives to intravenously administered factor IX products and bypass agents. These nonfactor therapies include Pfizer’s marstacimab, Novo Nordisk’s concizumab, and Sanofi’s fitusiran. Supported by insights from thought leaders, we analyze the impact of new drug therapies on the treatment of hemophilia B.
Questions answered
Geography
United States, EU5, Japan
Primary research
19 country-specific interviews with thought-leading hematologists
Supported by survey data collected for this and other Clarivate research
Epidemiology
Diagnosed prevalence of hemophilia B +/- inhibitors by country, population segmentation by disease severity and inhibitor titer
Forecast
10-year, annualized,drug-level sales and patient share of key hemophilia B therapies through 2032, segmented by brands and epidemiological subpopulations
Emerging therapies
Phase 3/PR: 5 drugs; Phase 2: 1 drug
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancements
Disease Landscape & Forecast is updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.